a proto-oncogenic receptor tyrosine kinase of the EGFR family. Essential component of a neuregulin-receptor complex, although neuregulins do not interact with it alone. Not activated by EGF, TGF- alpha and amphiregulin. Amplified in breast cancer. Overexpression induces constitutive activity, and the gene is amplified or overexpressed in up to 30% of breast cancers, correlating with poor survival. The antibody Herceptin is approved for treatment of metastatic breast cancer with HER2 amplification/overexpression. Somatic mutations seen in 4% of lung cancers and also in breast, gastric, ovarian cancer and glioblastoma. One SNP shows predisposition to breast and gastric cancer. Inhibitors: Herceptin, lapatinib, PKI-166, EKB-569, CI-1033. Note: This description may include information from UniProtKB.
Protein type: Protein kinase, TK; Protein kinase, tyrosine (receptor); Membrane protein, integral; Kinase, protein; EC 188.8.131.52; Oncoprotein; TK group; EGFR family
Cellular Component: apical plasma membrane; basal plasma membrane; basolateral plasma membrane; cytoplasm; cytoplasmic vesicle; endosome membrane; integral to membrane; lateral loop; lipid raft; microvillus; myelin sheath; nucleus; perinuclear region of cytoplasm; plasma membrane; postsynaptic membrane; receptor complex
Molecular Function: ATP binding; DNA binding; glycoprotein binding; growth factor binding; Hsp90 protein binding; identical protein binding; protein binding; protein C-terminus binding; protein heterodimerization activity; protein phosphatase binding; protein-tyrosine kinase activity; receptor signaling protein tyrosine kinase activity; transmembrane receptor activity; transmembrane receptor protein tyrosine kinase activity; ubiquitin protein ligase binding
Biological Process: cell surface receptor linked signal transduction; central nervous system development; glial cell differentiation; heart development; liver development; mammary gland involution; motor axon guidance; myelination; negative regulation of apoptosis; negative regulation of immature T cell proliferation in the thymus; nervous system development; neuromuscular junction development; oligodendrocyte differentiation; peptidyl-tyrosine phosphorylation; peripheral nervous system development; phosphoinositide 3-kinase cascade; positive regulation of cell adhesion; positive regulation of cell growth; positive regulation of cell proliferation; positive regulation of epithelial cell proliferation; positive regulation of GTPase activity; positive regulation of MAP kinase activity; positive regulation of MAPKKK cascade; positive regulation of phosphoinositide 3-kinase cascade; positive regulation of protein amino acid phosphorylation; positive regulation of Ras protein signal transduction; positive regulation of transcription from RNA polymerase I promoter; positive regulation of transcription from RNA polymerase III promoter; positive regulation of translation; protein amino acid autophosphorylation; regulation of cell differentiation; regulation of cell proliferation; regulation of microtubule-based process; response to axon injury; response to drug; response to progesterone stimulus; signal transduction; skeletal muscle development; sympathetic nervous system development; tongue development; transcription, DNA-dependent; transmembrane receptor protein tyrosine kinase signaling pathway; wound healing
LTP: The number of records in which this modification site was determined using site-specific methods. SS methods include amino acid sequencing, site-directed mutagenesis, modification site-specific antibodies, specific MS strategies, etc.